Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sonnet BioTherapeutics Holdings, Inc. - Common Stock (NQ:SONN)

1.225 +0.075 (+6.52%)
Streaming Delayed Price Updated: 1:22 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonnet BioTherapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 Next >
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
Via ACCESSWIRE
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Via ACCESSWIRE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Via ACCESSWIRE
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Via ACCESSWIRE
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
Via ACCESSWIRE
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
Via ACCESSWIRE
Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
Via ACCESSWIRE
Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
Via ACCESSWIRE
Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.